Background: Head and neck cancer, mostly squamous cell carcinoma, ranks sixth among the most common cancers. Despite progress in treatment in recent years, survival remains poor. Since induction chemotherapy has been associated with survival benefit, it is a reasonable treatment option. The standard protocol up to recently has been cisplatin and 5-flourouracil. The addition of taxanes to the standard induction protocol has shown superiority in terms of the overall response rate. Nevertheless, not all trials demonstrated survival benefit. We aimed to evaluate the effect of taxane added to the standard protocol of induction therapy.
Methods: We performed a systematic review and meta-analysis of randomized controlled trials that compared the addition of taxane to the standard induction protocol of cisplatin and 5-flourouracil for patients with head and neck malignancy. We searched The Cochrane library, PubMed, LILACS, conference proceedings, and references of published trials. Two reviewers independently assessed the quality of the trials and extracted data. Hazard ratios (HRs) for time-to-event were determined and pooled.
Results: A total of 4 trials comprising 1,441 patients were included in this meta-analysis. All patients were available for the meta-analysis of overall survival. Patients treated with the addition of taxane had statistically significant overall survival [HR = 0.82, 95% confidence interval (CI) 0.71-0.94] and progression-free survival (HR = 0.82, 95% CI 0.72-0.93). No effect was observed in larynx preservation rate (relative risk = 0.88, 95% CI 0.64-1.19). The rate of hematological adverse events was higher in the taxane group than in the control group.
Conclusions: These results suggest that induction therapy with the addition of taxane is superior to induction therapy with cisplatin and 5-flourouracil in terms of overall survival and progression-free survival. The higher rate of neutropenia and neutropenic fever should be taken into consideration when making treatment decisions.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000360690 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
On the Role of Hydrogen Migrations in the Taxadiene System.
Angew Chem Int Ed Engl
January 2025
University of Bonn: Rheinische Friedrich-Wilhelms-Universitat Bonn, Kekulé Institute for Organic Chemistry and Biochemistry, Gerhard-Domagk-Straße 1, 53121, Bonn, GERMANY.
Taxa-4,11-diene is made by the taxa-4,11-diene synthase (TxS) from Taxus brevifolia. The unique reactivity of the taxane system is characterised by long distance hydrogen migrations in the biosynthesis. This study demonstrates that selective long range hydrogen migrations also play a role in the high energy process of the EI-MS fragmentation of taxa-4,11-diene.
View Article and Find Full Text PDFSupraclavicular Irradiation Induces Lymphedema in Breast Cancer Patients Treated with Axillary Lymph Node Dissection and Taxane-Containing Chemotherapy.
Breast J
January 2025
Department of Breast Oncology Aichi Cancer Center, 1-1, Kanokoden, Chikusa-ku, Nagoya 464-8681, Aichi, Japan.
Article Synopsis
- Breast cancer-related lymphedema (LE) negatively affects quality of life, with axillary lymph node dissection (ALND) and postoperative docetaxel (DTX) being significant risk factors.
- Among 214 patients studied, 24% developed objective LE, with supraclavicular irradiation identified as a key risk factor, more so when combined with taxane chemotherapy.
- The findings highlight the need for careful management of LE in patients undergoing both taxane-based treatments and supraclavicular radiation therapy.
Ether-Linked Glycerophospholipids Are Potential Chemo-Desensitisers and Are Associated With Overall Survival in Carcinoma Patients.
J Cell Mol Med
December 2024
Graduate Institute of Biomedical Sciences, Program for MD/PhD, Research Center for Cancer Biology, School of Medicine, China Medical University, Taichung, Taiwan.
Article Synopsis
- Lipid reprogramming plays a significant role in cancer development, prognosis, and response to treatment, with both autonomous and nonautonomous sources contributing to this process.
- Research has identified ether-linked phosphatidyl-ethanolamine (PE O-) as a key lipid that enhances resistance to chemotherapy and promotes tumor progression in epithelial ovarian cancer (EOC).
- Analysis revealed that PE O- is associated with reduced sensitivity to common chemotherapy drugs (cisplatin/paclitaxel) and its gene expression correlates positively with patient outcomes, suggesting that targeting PE O- could improve treatment effectiveness in EOC.
Impaired liver function: effect on paclitaxel toxicity, dose modifications and overall survival.
BMC Cancer
December 2024
Department of Clinical Pharmacy, University Medical Center Utrecht, PO Box 85500, Utrecht, 3508 GA, The Netherlands.
Article Synopsis
- The study examines how impaired liver function affects the toxicity of the anticancer drug paclitaxel, specifically focusing on hematological complications, dose modifications, and overall survival rates in cancer patients.
- It analyzes data from 569 patients treated at the University Medical Centre Utrecht between 2011 and 2022, comparing those with normal and impaired liver function based on specific medical criteria.
- Results show that patients with liver impairment experienced significantly higher risks of severe neutropenia and leukopenia, required more dose modifications, and had poorer overall survival in cases of inoperable esophageal and advanced ovarian cancers.
Purpose: SWOG S1815 was a randomized, open label phase III trial, evaluating gemcitabine, nab-paclitaxel, and cisplatin (GAP) versus gemcitabine and cisplatin (GC) in patients with newly diagnosed advanced biliary tract cancers (BTCs).
Methods: Patients with newly diagnosed locally advanced unresectable or metastatic BTC, including intrahepatic cholangiocarcinoma (ICC) and extrahepatic cholangiocarcinoma (ECC) and gallbladder carcinoma (GBC), were randomly assigned 2:1 to either GAP (gemcitabine 800 mg/m, cisplatin 25 mg/m, and nab-paclitaxel 100 mg/m intravenously once per day on days 1 and 8 of a 21-day cycle) or GC (gemcitabine 1,000 mg/m and cisplatin 25 mg/m intravenously once per day on days 1 and 8 of a 21-day cycle).
Results: Among 452 randomly assigned participants, 441 were eligible and analyzable, 67% with ICC, 16% with GBC, and 17% with ECC.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!